Alnylam Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 165 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 22.10B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 2500 |
| Founded | 2002 |
| Ipo Date | 2004-05-28 |
| Ceo | Yvonne Greenstreet |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US02043Q1076 |
| Cusip | 02043Q107 |
| Cik | 0001178670 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | Chief Executive Officer and Director |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
| Jeffrey V. Poulton M.B.A. | Chief Financial Officer and Executive Vice President |
| Bryan Andrew Supran J.D. | Chief Legal Officer |
| Dr. Pushkal P. Garg M.D. | Executive Vice President and Chief Research & Development Officer |
| Tolga Tanguler M.B.A. | Executive Vice President and Chief Commercialization Officer |
| Timothy J. Maines | Chief Technical Operations and Quality Officer |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Early Research and Early Development |
| Joshua Brodsky | Vice President of Investor Relations |
| Piyush Sharma J.D. | Chief Ethics and Compliance Officer |
Contact
| Address | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142, United States |
| Phone | 617 551 8200 |
| Website | https://www.alnylam.com |